Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

1.

Influence of hepatic impairment on the pharmacokinetics of the dopamine agonist rotigotine.

Cawello W, Fichtner A, Boekens H, Braun M.

Eur J Drug Metab Pharmacokinet. 2014 Sep;39(3):155-63. doi: 10.1007/s13318-013-0153-x. Epub 2013 Sep 20.

PMID:
24052490
[PubMed - in process]
2.

Single dose pharmacokinetics of the transdermal rotigotine patch in patients with impaired renal function.

Cawello W, Ahrweiler S, Sulowicz W, Szymczakiewicz-Multanowska A, Braun M.

Br J Clin Pharmacol. 2012 Jan;73(1):46-54. doi: 10.1111/j.1365-2125.2011.04053.x.

PMID:
21707699
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Influence of domperidone on pharmacokinetics, safety and tolerability of the dopamine agonist rotigotine.

Braun M, Cawello W, Boekens H, Horstmann R.

Br J Clin Pharmacol. 2009 Feb;67(2):209-15. doi: 10.1111/j.1365-2125.2008.03334.x. Epub 2008 Dec 16.

PMID:
19094160
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Pharmacokinetics, safety and tolerability of rotigotine transdermal patch in healthy Japanese and Caucasian subjects.

Cawello W, Kim SR, Braun M, Elshoff JP, Ikeda J, Funaki T.

Clin Drug Investig. 2014 Feb;34(2):95-105. doi: 10.1007/s40261-013-0150-5.

PMID:
24178238
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Influence of transdermal rotigotine on ovulation suppression by a combined oral contraceptive.

Braun M, Elshoff JP, Andreas JO, Müller LI, Horstmann R.

Br J Clin Pharmacol. 2009 Sep;68(3):386-94. doi: 10.1111/j.1365-2125.2009.03468.x.

PMID:
19740396
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal function.

Treitel M, Marbury T, Preston RA, Triantafyllou I, Feely W, O'Mara E, Kasserra C, Gupta S, Hughes EA.

Clin Pharmacokinet. 2012 Sep 1;51(9):619-28. doi: 10.2165/11633440-000000000-00000.

PMID:
22799589
[PubMed - indexed for MEDLINE]
7.

Pharmacokinetics of linagliptin in subjects with hepatic impairment.

Graefe-Mody U, Rose P, Retlich S, Ring A, Waldhauser L, Cinca R, Woerle HJ.

Br J Clin Pharmacol. 2012 Jul;74(1):75-85. doi: 10.1111/j.1365-2125.2012.04173.x.

PMID:
22242621
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Pharmacokinetics and pharmacodynamics of cinacalcet in hepatic impairment : phase I, open-label, parallel-group, single-dose, single-centre study.

Padhi D, Harris RZ, Salfi M, Noveck RJ, Sullivan JT.

Clin Drug Investig. 2008;28(10):635-43.

PMID:
18783302
[PubMed - indexed for MEDLINE]
9.

Asenapine pharmacokinetics in hepatic and renal impairment.

Peeters P, Bockbrader H, Spaans E, Dogterom P, Lasseter K, Marbury T, Gibson GL, de Greef R.

Clin Pharmacokinet. 2011 Jul;50(7):471-81. doi: 10.2165/11590490-000000000-00000.

PMID:
21651314
[PubMed - indexed for MEDLINE]
10.

Pharmacokinetics of vandetanib in subjects with renal or hepatic impairment.

Weil A, Martin P, Smith R, Oliver S, Langmuir P, Read J, Molz KH.

Clin Pharmacokinet. 2010 Sep;49(9):607-18. doi: 10.2165/11534330-000000000-00000.

PMID:
20690783
[PubMed - indexed for MEDLINE]
11.

Effect of renal or hepatic impairment on the pharmacokinetics of mirabegron.

Dickinson J, Lewand M, Sawamoto T, Krauwinkel W, Schaddelee M, Keirns J, Kerbusch V, Moy S, Meijer J, Kowalski D, Morton R, Lasseter K, Riff D, Kupčová V, van Gelderen M.

Clin Drug Investig. 2013 Jan;33(1):11-23. doi: 10.1007/s40261-012-0031-3.

PMID:
23208320
[PubMed - indexed for MEDLINE]
12.

Pharmacokinetics of vilazodone in patients with mild or moderate renal impairment.

Boinpally R, Alcorn H, Adams MH, Longstreth J, Edwards J.

Clin Drug Investig. 2013 Mar;33(3):199-206. doi: 10.1007/s40261-013-0061-5.

PMID:
23417352
[PubMed - indexed for MEDLINE]
13.

Effects of hepatic impairment on the pharmacokinetics of nilotinib: an open-label, single-dose, parallel-group study.

Yin OQ, Gallagher N, Tanaka C, Fisher D, Sethuraman V, Zhou W, Lin TH, Heuman D, Schran H.

Clin Ther. 2009;31 Pt 2:2459-69. doi: 10.1016/j.clinthera.2009.11.015.

PMID:
20110053
[PubMed - indexed for MEDLINE]
14.

Pharmacokinetics of intravenous conivaptan in subjects with hepatic or renal impairment.

Roy MJ, Erdman KA, Abeyratne AT, Plumb LC, Lasseter K, Riff DS, Keirns JJ.

Clin Pharmacokinet. 2013 May;52(5):385-95. doi: 10.1007/s40262-013-0047-8.

PMID:
23456393
[PubMed - indexed for MEDLINE]
15.

The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil.

Muirhead GJ, Wilner K, Colburn W, Haug-Pihale G, Rouviex B.

Br J Clin Pharmacol. 2002;53 Suppl 1:21S-30S.

PMID:
11879256
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Steady-state plasma concentration profile of transdermal rotigotine: an integrated analysis of three, open-label, randomized, phase I multiple dose studies.

Elshoff JP, Braun M, Andreas JO, Middle M, Cawello W.

Clin Ther. 2012 Apr;34(4):966-78. doi: 10.1016/j.clinthera.2012.02.008. Epub 2012 Mar 7.

PMID:
22401642
[PubMed - indexed for MEDLINE]
17.

The effects of degree of hepatic or renal impairment on the pharmacokinetics of exemestane in postmenopausal women.

Jannuzzo MG, Poggesi I, Spinelli R, Rocchetti M, Cicioni P, Buchan P.

Cancer Chemother Pharmacol. 2004 Jun;53(6):475-81. Epub 2004 Mar 11.

PMID:
15014897
[PubMed - indexed for MEDLINE]
18.

Tolerability and pharmacokinetics of ranolazine following single and multiple sustained-release doses in Chinese healthy adult volunteers: a randomized, open-label, Latin square design, phase I study.

Tan QY, Li HD, Zhu RH, Zhang QZ, Zhang J, Peng WX.

Am J Cardiovasc Drugs. 2013 Feb;13(1):17-25. doi: 10.1007/s40256-013-0006-7.

PMID:
23355361
[PubMed - indexed for MEDLINE]
19.

Influence of renal and hepatic impairment on the pharmacokinetic and pharmacodynamic properties and tolerability of fluticasone furoate and vilanterol in combination.

Allen A, Davis A, Hardes K, Tombs L, Kempsford R.

Clin Ther. 2012 Dec;34(12):2316-32. doi: 10.1016/j.clinthera.2012.11.001. Epub 2012 Nov 30.

PMID:
23200625
[PubMed - indexed for MEDLINE]
20.

Pharmacokinetics and tolerability of zibotentan (ZD4054) in subjects with hepatic or renal impairment: two open-label comparative studies.

Tomkinson H, Kemp J, Oliver S, Swaisland H, Taboada M, Morris T.

BMC Clin Pharmacol. 2011 Mar 17;11:3. doi: 10.1186/1472-6904-11-3.

PMID:
21414193
[PubMed - indexed for MEDLINE]
Free PMC Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk